Eli Lilly & Co. (NYSE:LLY)

pet cat

2 Animal Health Stocks Still Look Attractive for Investors

If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a ...
Read Full Story »
Light Switch

Merrill Lynch Makes a Huge Change to Prestigious US 1 Portfolio

With earnings for the third quarter on deck, and the fourth quarter of 2016 almost underway, many of the top companies we follow on Wall Street are making some changes ...
Read Full Story »
clinical trials

Jefferies Issues Top Pharma and Biohealth Stocks to Buy

Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward. One key analyst issued a few of its top picks ...
Read Full Story »
Procter & Gamble

4 Safe Large Cap Dividend Stocks to Buy as Market Risk Increases

Friday reminded everybody of just how long we have a gone without a 1% or greater sell-off, and the volatility has jumped big time. Of course the big scare that ...
Read Full Story »
bull and bear

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

It is sometimes hard to wonder about health care and pharmaceutical stocks during an election year. Still, with uncertainty can come opportunity. The team at Credit Suisse has issued its ...
Read Full Story »
Prescription drugs

Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick

Health care has lagged the top sectors in the S&P 500 over the past year, but it is starting to catch up and some nice moves in the big pharmaceutical ...
Read Full Story »
Medicine pills

Why Eli Lilly Earnings Are So Dynamic

Eli Lilly and Co. (NYSE: LLY) released its second-quarter earnings report before the markets opened on Tuesday. Currently this company is in the middle of a very dynamic product launch, ...
Read Full Story »
Medicine pills

Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016

Ever since the Hillary Clinton high drug price tweet in September of last year, the major pharmaceuticals and biotechs have struggled, and while performance has improved over the past quarter, ...
Read Full Story »
Medicine pills

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

If one sector has struggled this year it has been the health care sector, which is surprising given that usually it is considered to be very defensive. But ever since a ...
Read Full Story »
happy couple

Viagra Price Drops 50% as Drug Faces Competition

Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year, and direct competitors Levitra and Cialis. In the face of these, Viagra has ...
Read Full Story »
Medicine pills

Eli Lilly Rises on Positive FDA Committee Vote

Eli Lilly and Co. (NYSE: LLY) is watching its shares make a decent gain on Wednesday following a U.S. Food and Drug Administration (FDA) vote. The FDA Advisory Committee voted ...
Read Full Story »
investing

4 Merrill Lynch US 1 Portfolio Stocks With Big Total Return Potential

We always like to remind our readers about the impact total return has on portfolios because it is one of the best ways to help improve the chances for overall ...
Read Full Story »
Medicine pills

How Credit Suisse Views Major Pharma After ASCO

The American Society of Clinical Oncology (ASCO) annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations ...
Read Full Story »
Female patient on gurney

Merrill Lynch Picks ASCO Winners

The health care sector is descending on Chicago as the American Society of Clinical Oncology (ASCO) annual meeting nears. This meeting draws many companies and analysts alike, looking for the ...
Read Full Story »
Doctor, Health (pulse) copy

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is in the process of gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their ...
Read Full Story »